Drug Profile
HMR 4004
Latest Information Update: 02 Oct 2001
Price :
$50
*
At a glance
- Originator Aventis
- Class Antibacterials; Ketolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial endocarditis
Most Recent Events
- 02 Oct 2001 No-Development-Reported for Bacterial endocarditis in USA (Unknown route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 21 Apr 1999 New profile